KV Pharmaceutical emerges from bankruptcy #pharmacology #companies

Posted On May 18 2017 by

#kv pharma # KV Pharmaceutical emerges from bankruptcy KV Pharmaceutical Co. has emerged from bankruptcy with less debt and a $375 million recapitalization. The Bridgeton-based drug company said that as part of its plan of reorganization, effective Monday, its current preferred and common stock had been canceled. Current senior secured notes will be paid in cash, and general unsecured creditors will receive a pro rata share of $10.25 million, KV said in a statement. Convertible subordinated noteholders will receive 7 percent of KV’s new common shares in addition to shares purchased through the rights offering or direct purchase of shares. …


FDA Takes Action Against KV Pharmaceutical Company #pharma #brands

Posted On May 2 2017 by

#kv pharma # Media Inquiries:Rita Chappelle, 301-796-4672Consumer Inquiries:888-INFO-FDA FDA Takes Action Against KV Pharmaceutical CompanyCompany Making, Marketing and Distributing Adulterated and Unapproved Drugs The FDA announced a Consent Decree of permanent injunction filed March 2, 2009, enjoining KV Pharmaceutical Company, its subsidiaries ETHEX Corporation and Ther-Rx Corporation, and its principal officers from making and distributing adulterated and unapproved drugs. The injunction against KV and the other defendants, once entered by the court, will prevent them from manufacturing and shipping drugs until the firm obtains FDA approval. It will remain in place until the defendants sustain continuous compliance with FDA’s current …


KV Pharma – Pharma manufacturing consent decrees #small #pharma #companies

Posted On Apr 23 2017 by

#kv pharma # KV Pharma – Pharma manufacturing consent decrees Product recalls involving oversized tablets and other causes, which followed FDA discovery of manufacturing problems in a 2008 inspection, ultimately led to this far-reaching consent decree. It stretches beyond KV to subsidiaries Ther-Rx and ETHEX, all three of which were forced to stop manufacturing and distribution operations due to adulteration and, for some drugs, lack of market approval. ETHEX, ultimately, was shuttered. The regulator enlisted the help of U.S. Marshalls, who seized more than $24 million in products following KV’s continued production after the FDA-ordered halt. KV hired GMP expert …


KV Pharma – Pharma manufacturing consent decrees #www.buy-pharma.com

Posted On Apr 13 2017 by

#kv pharma # KV Pharma – Pharma manufacturing consent decrees Product recalls involving oversized tablets and other causes, which followed FDA discovery of manufacturing problems in a 2008 inspection, ultimately led to this far-reaching consent decree. It stretches beyond KV to subsidiaries Ther-Rx and ETHEX, all three of which were forced to stop manufacturing and distribution operations due to adulteration and, for some drugs, lack of market approval. ETHEX, ultimately, was shuttered. The regulator enlisted the help of U.S. Marshalls, who seized more than $24 million in products following KV’s continued production after the FDA-ordered halt. KV hired GMP expert …


KV Pharmaceutical emerges from bankruptcy #pharma #consulting #companies

Posted On Apr 6 2017 by

#kv pharma # KV Pharmaceutical emerges from bankruptcy KV Pharmaceutical Co. has emerged from bankruptcy with less debt and a $375 million recapitalization. The Bridgeton-based drug company said that as part of its plan of reorganization, effective Monday, its current preferred and common stock had been canceled. Current senior secured notes will be paid in cash, and general unsecured creditors will receive a pro rata share of $10.25 million, KV said in a statement. Convertible subordinated noteholders will receive 7 percent of KV’s new common shares in addition to shares purchased through the rights offering or direct purchase of shares. …


KV Pharmaceutical emerges from bankruptcy #pharmaceutical #business #plan

Posted On Mar 24 2017 by

#kv pharma # KV Pharmaceutical emerges from bankruptcy KV Pharmaceutical Co. has emerged from bankruptcy with less debt and a $375 million recapitalization. The Bridgeton-based drug company said that as part of its plan of reorganization, effective Monday, its current preferred and common stock had been canceled. Current senior secured notes will be paid in cash, and general unsecured creditors will receive a pro rata share of $10.25 million, KV said in a statement. Convertible subordinated noteholders will receive 7 percent of KV’s new common shares in addition to shares purchased through the rights offering or direct purchase of shares. …


FDA Takes Action Against KV Pharmaceutical Company #generic #pharmaceutical #industry

Posted On Feb 6 2017 by

#kv pharma # Media Inquiries:Rita Chappelle, 301-796-4672Consumer Inquiries:888-INFO-FDA FDA Takes Action Against KV Pharmaceutical CompanyCompany Making, Marketing and Distributing Adulterated and Unapproved Drugs The FDA announced a Consent Decree of permanent injunction filed March 2, 2009, enjoining KV Pharmaceutical Company, its subsidiaries ETHEX Corporation and Ther-Rx Corporation, and its principal officers from making and distributing adulterated and unapproved drugs. The injunction against KV and the other defendants, once entered by the court, will prevent them from manufacturing and shipping drugs until the firm obtains FDA approval. It will remain in place until the defendants sustain continuous compliance with FDA’s current …


KV Pharma – Pharma manufacturing consent decrees #dsm #pharma

Posted On Feb 6 2017 by

#kv pharma # KV Pharma – Pharma manufacturing consent decrees Product recalls involving oversized tablets and other causes, which followed FDA discovery of manufacturing problems in a 2008 inspection, ultimately led to this far-reaching consent decree. It stretches beyond KV to subsidiaries Ther-Rx and ETHEX, all three of which were forced to stop manufacturing and distribution operations due to adulteration and, for some drugs, lack of market approval. ETHEX, ultimately, was shuttered. The regulator enlisted the help of U.S. Marshalls, who seized more than $24 million in products following KV’s continued production after the FDA-ordered halt. KV hired GMP expert …


KV Pharmaceutical emerges from bankruptcy #watson #pharma

Posted On Feb 6 2017 by

#kv pharma # KV Pharmaceutical emerges from bankruptcy KV Pharmaceutical Co. has emerged from bankruptcy with less debt and a $375 million recapitalization. The Bridgeton-based drug company said that as part of its plan of reorganization, effective Monday, its current preferred and common stock had been canceled. Current senior secured notes will be paid in cash, and general unsecured creditors will receive a pro rata share of $10.25 million, KV said in a statement. Convertible subordinated noteholders will receive 7 percent of KV’s new common shares in addition to shares purchased through the rights offering or direct purchase of shares. …


KV Pharma – Pharma manufacturing consent decrees #pharmaceutical #conference

Posted On Jan 10 2017 by

#kv pharma # KV Pharma – Pharma manufacturing consent decrees Product recalls involving oversized tablets and other causes, which followed FDA discovery of manufacturing problems in a 2008 inspection, ultimately led to this far-reaching consent decree. It stretches beyond KV to subsidiaries Ther-Rx and ETHEX, all three of which were forced to stop manufacturing and distribution operations due to adulteration and, for some drugs, lack of market approval. ETHEX, ultimately, was shuttered. The regulator enlisted the help of U.S. Marshalls, who seized more than $24 million in products following KV’s continued production after the FDA-ordered halt. KV hired GMP expert …